Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | DUSP22 | Q9NRW4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632930 | 0.96 | ALDH1A1 (0.46) | ALDH1A1ALKTDP1JAK2KMT2A | |
| SCHEMBL4363395 | 0.92 | ALK (0.49) | ALDH1A1ALKJAK2LMNAUSP2 | |
| SCHEMBL1076245 | 0.88 | ALK (0.50) | ALDH1A1ALKTDP1JAK2KMT2A | |
| Trifluoroacetic Acid SCHEMBL4361561 | 0.88 | ALK (0.46) | ALDH1A1ALKJAK2LMNA | |
| SCHEMBL13632936 | 0.86 | ALK (0.40) | ALKJAK2MAPTRAB9A | |
| SCHEMBL13633046 | 0.85 | ALK (0.44) | ALKJAK2KMT2ATSHRRAB9A | |
| Trifluoroacetic Acid SCHEMBL4359246 | 0.84 | ALK (0.46) | ALDH1A1ALKTDP1JAK2KMT2A | |
| SCHEMBL4357322 | 0.84 | ALK (0.51) | ALDH1A1ALKTDP1JAK2KMT2A | |
| SCHEMBL4364967 | 0.83 | ALK (0.51) | ALDH1A1ALKJAK2 | |
| SCHEMBL4362936 | 0.83 | ALK (0.54) | ALDH1A1ALKJAK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885ALK 3/4885TDP1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.